Newsletter Tool

Today’s Big News

Jul 8, 2025

Taiho’s DMD asset fails to improve functional motor test results in phase 3 trial

Concentra extends biotech shopping spree by collecting Cargo

CSL trims R&D team, shifts focus toward external opportunities

Rallybio shifts gears, cashing out of Recursion pact to extend runway

ProKidney’s CKD cell therapy scores win in one half of phase 2 trial, falls short on other

Novartis' malaria drug for babies wins world-first approval

Cell therapy biotech shares first clinical data for in vivo CAR-T that attracted $1B AstraZeneca acquisition

Basilea secures $39M from BARDA as part of long-term antifungal funding plan

Featured

Taiho’s DMD asset fails to improve functional motor test results in phase 3 trial

By Gabrielle Masson

Taiho Pharmaceutical’s investigational treatment for Duchenne muscular dystrophy (DMD) has failed to impact the time it takes patients to rise from the floor over 52 weeks, missing the phase 3 study’s main goal.

Concentra extends biotech shopping spree by collecting Cargo

By James Waldron

Many of Concentra’s targets are biotechs that have found themselves in tough times, and Cargo certainly fits the bill.

CSL trims R&D team, shifts focus toward external opportunities

By Gabrielle Masson

CSL is consolidating its R&D team in an effort to better position the organization “for long-term success in a rapidly evolving global environment.”

SAP, Answerthink Help Emerging Biopharma Firms Scale With Confidence

Rallybio shifts gears, cashing out of Recursion pact to extend runway

By Nick Paul Taylor

Rallybio has swerved away from its Recursion Pharmaceuticals pact, accepting $7.5 million upfront for its share of a preclinical program to extend its cash runway to mid-2027.

ProKidney’s CKD cell therapy scores win in one half of phase 2 trial, falls short on other

By James Waldron

ProKidney’s cell therapy for kidney disease has failed to demonstrate a clinically significant preservation of kidney function in one part of a phase 2 study.

Novartis' malaria drug for babies wins world-first approval

By Kevin Dunleavy

Novartis and a Swiss nonprofit have made history, scoring the world’s first approval for a medicine to treat babies who are infected with malaria. The nod is for a new formulation of Coartem, which is also known commercially in come countries as Riamet.

Cell therapy biotech shares first clinical data for in vivo CAR-T that attracted $1B AstraZeneca acquisition

By Darren Incorvaia

Months after announcing an M&A deal with AstraZeneca, EsoBiotec has released the first small slice of data on the cell therapy asset that attracted the Big Pharma’s attention. Four patients with multiple myeloma who received the Belgian biotech’s in vivo T-cell editing therapy all responded to treatment, with the cancer of two patients resolving completely.

Basilea secures $39M from BARDA as part of long-term antifungal funding plan

By James Waldron

Basilea Pharmaceutica has accessed the next tranche of U.S. government funding required to continue developing its pipeline of new antifungals.

Fierce podcasts

Don’t miss an episode

Teva’s CEO shares ‘Pivot to Growth’ progress

In this episode of "The Top Line," Teva CEO Richard Francis shares progress on the company’s “Pivot to Growth” strategy and what lies ahead.

Rethinking the mental healthcare model

AbbVie, ADCs and the future of cancer care

Resources

Whitepaper

Industry-backed, data-driven approaches to enhancing container closure integrity

This white paper outlines how we apply industry-backed practices and proprietary technologies to proactively safeguard sterility and performance.

How Will US Policy Impact the Growth of UK Biotech?

Presented by Blue Matter, strategic consultants in the life sciences

Specialized Support to Accelerate Biotech Success

Biotech innovation doesn’t slow down—and neither should your lab partner. This brief outlines how early scientific engagement, operational transparency, and integrated global lab services help reduce risk, stay on schedule, and deliver results. Whether you're navigating your first trial or scaling a growing pipeline, see how a purpose-built lab model can help you move smarter and faster.